Evidence map›Paper›PMID 30378794›Full record

ArticlePediatric endocrinology reviews : PER2018

Long-Acting Growth Hormone Preparations in the Treatment of Children.

Rayhan A Lal, Andrew R Hoffman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric endocrinology reviews : PER, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. PEGylated therapeutics in the clinic.Bioengineering & translational medicine · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Management of Hypopituitarism.Journal of clinical medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rayhan A LalDivision of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA, Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA, E-mail: inforay@stanford.edu.
Andrew R HoffmanDivision of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA 3Medical Service, VA Palo Alto Health Care System, Palo Alto, California, USA.
Stanford University · US

Funding

Diabetes, Endocrinology and Metabolism Training GrantT32DK007217 · NIDDK · STANFORD UNIVERSITY · PI Justin Pierce Annes, David Matthew Maahs · 1987 to 2026
$7.2M
Training Research Leaders in Type 1 DiabetesK12DK122550 · NIDDK · STANFORD UNIVERSITY · PI MAAHS, DAVID MATTHEW · 2019 to 2023
$2.1M
NIDDK NIH HHS K12 DK122550NIDDK NIH HHS T32 DK007217
6 · The paper itself

Abstract

Human growth hormone (hGH), which had been in use since 1958, was supplanted by recombinant human growth hormone (rhGH) in 1985 for those with growth hormone deficiency (GHD). Adherence to daily subcutaneous growth hormone is challenging for patients. Thus, several companies have pursued the creation of long acting rhGH. These agents can be divided broadly into depot formulations, PEGylated formulations, pro-drug formulations, non-covalent albumin binding GH and GH fusion proteins. Nutropin Depot is the only long acting rhGH ever approved by the U.S. Food and Drug Administration, and it was removed from the market in 2004. Of the approximately seventeen candidate drugs, only a handful remain under active clinical investigation or are commercially available.

Indexed as

Dwarfism, PituitaryChildDelayed-Action PreparationsHuman Growth HormoneHumansInsulin-Like Growth Factor IRecombinant ProteinsDelayed-Action PreparationsHuman Growth HormoneInsulin-Like Growth Factor IRecombinant ProteinsAdultChildChildrenDrug formulationGrowth hormoneGrowth hormone deficiencyLong-actingNovel treatmentPediatric

Identifiers

PMID30378794
PMCPMC6438189
OpenAlexW2899806045

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.